BTC $62,995.90 -0.20%
ETH $1,881.25 -0.15%
BNB $610.72 +0.69%
XRP $1.00 -0.11%
SOL $75.48 -0.11%
TRX $0.3315 -0.14%
DOGE $0.0699 -0.15%
ADA $0.1770 -1.83%
BCH $205.95 +1.09%
LINK $9.60 +7.59%
HYPE $56.94 +1.76%
AAVE $86.82 +0.07%
SUI $0.6818 +0.55%
XLM $0.1592 -0.53%
ZEC $488.45 -0.68%
BTC $62,995.90 -0.20%
ETH $1,881.25 -0.15%
BNB $610.72 +0.69%
XRP $1.00 -0.11%
SOL $75.48 -0.11%
TRX $0.3315 -0.14%
DOGE $0.0699 -0.15%
ADA $0.1770 -1.83%
BCH $205.95 +1.09%
LINK $9.60 +7.59%
HYPE $56.94 +1.76%
AAVE $86.82 +0.07%
SUI $0.6818 +0.55%
XLM $0.1592 -0.53%
ZEC $488.45 -0.68%

Sonnet Biotherapeutics has received shareholder approval to merge with Hyperliquid Strategies Inc

2025-12-02 22:26:45

According to market news, Nasdaq-listed biotech company Sonnet Biotherapeutics has received shareholder approval to merge with Hyperliquid Strategies Inc.

Previously, it was reported that Hyperliquid Strategies submitted an S-1 filing to raise up to $1 billion, which may be used to purchase HYPE tokens.

app_icon
ChainCatcher Building the Web3 world with innovations.